SCHEMBL1052230

SCHEMBL1052230

NC(=O)NCc1cccc(C(F)(F)F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.63
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
PLA2G1B P04054 1/20 0.62
CYP1A2 P05177 1/20 0.62
CYP3A4 P08684 1/20 0.62
GAA P10253 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
ATG4B Q9Y4P1 1/20 0.62
L3MBTL1 Q9Y468 1/20 0.59
LMNA P02545 1/20 0.58
HPGD P15428 1/20 0.58
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
MAPK14 Q16539 1/20 0.56
EPHX1 P07099 2/20 0.55
NR3C2 P08235 1/20 0.54
RPS6KB1 P23443 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31173731 1.00 MLYCD (0.63) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL29693545 0.88 MLYCD (0.60) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL4576177 0.88 MLYCD (0.60) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL24713109 0.87 MLYCD (0.67) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL30661718 0.85 MLYCD (0.65) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL11749179 0.84 CNR1 (0.61) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL13884195 0.84 L3MBTL1 (0.64) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL16108345 0.84 MEN1 (0.56) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL10310190 0.84 MLYCD (0.56) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL185921 0.84 MLYCD (0.63) MLYCDMEN1KMT2APLA2G1BCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111662275-A Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof 中国药科大学 2020-09-15 CN claimed
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
CN-111662275-B Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof 中国药科大学 2023-08-22 CN disclosed
US-20230136562-A1 SPIROUREA DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2023-05-04 US disclosed
CN-111662275-A Benzenesulfonamide IDH mutant inhibitor, preparation method and application thereof 中国药科大学 2020-09-15 CN disclosed
US-20180305231-A1 COMPOSITE, A METHOD OF MAKING THEREOF, AND A METHOD FOR DEGRADING A POLLUTANT KING ABDULAZIZ UNIVERSITY (SA) 2018-10-25 US disclosed
US-9751843-B2 Substituted uracils and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-05 US disclosed
US-9751843-B2 Substituted uracils and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-05 US disclosed
US-9751843-B2 Substituted uracils and use thereof BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-05 US disclosed
CN-103012378-A 3-phenyl-pyrazole derivatives as modulators of the 5-HT2a serotonin receptor useful for the treatment of disorders related thereto ARENA PHARM INC 2013-04-03 CN disclosed
CN-102977029-A 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARM INC 2013-03-20 CN disclosed
CN-101084195-B As 5-HT2A3-phenyl-pyrazole derivatives useful as serotonin receptor modulators for the treatment of disorders related thereto ARENA PHARM INC 2013-01-02 CN disclosed
US-20120183537-A1 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER BETAGENON AB 2012-07-19 US disclosed
CN-102596923-A 1,2, 4-thiazolidin-3-one derivatives and their use in the treatment of cancer BETAGENON AB 2012-07-18 CN disclosed
EP-2451794-A2 1,2,4-THIAZOLIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER BALTIC BIO AB (SE) 2012-05-16 EP disclosed
WO-2011016559-A1 HETEROCYCLIC COMPOUND AND USE THEREOF 武田薬品工業株式会社 (JP) 2011-02-10 WO disclosed
WO-2011004162-A2 COMPOUNDS USEFUL AS MEDICAMENTS BETAGENON AB (SE) 2011-01-13 WO disclosed
CN-101084195-A As 5-HT2A3-phenyl-pyrazole derivatives useful as serotonin receptor modulators for the treatment of disorders related thereto ARENA PHARM INC (US) 2007-12-05 CN disclosed
CN-1478084-A Compounds useful in treatment of inflammatory diseases 2004-02-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136562-A1 SPIROUREA DERIVATIVES KCNA7, PKD2, KCNN3 MLYCD 3830/4885MEN1 721/4885KMT2A 1711/4885
US-20120183537-A1 1,2,4-THIAZOLOIDIN-3-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER HCCS, CCND3, MTNR1A MLYCD 1090/4885MEN1 1511/4885KMT2A 1670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.